PROFESSIONAL EDITION

The largest community of pharma leaders

NOXXON Appoints Experienced Cancer Drug Developer Dr. Jose Saro as Chair of Scientific Advisory Board

BERLIN, Germany–(BUSINESS WIRE)–Regulatory News: NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX) a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today the formation of a Scientific Advisory Board (SAB) and the appointment of Jose Saro, M.D. as its Chair. Dr. Saro and the SAB will provide scientific and strategic advice to the company regarding research and development of its programs in cancer. “With NOXXON’s focus shar

Source Business Wire Health: Pharmaceutical NewsRead More

Recent Articles